三磷酸肌苷焦磷酸酶药理遗传学的研究进展

Pharmacogenetic research progress of inosine triphosphate pyrophosphatase

嘌呤类药物主要用于治疗自身免疫性疾病、器官移植、急性淋巴细胞白血病等，其不良反应的发生率为15％-28％，严重影响了药物在临床中的应用。三磷酸肌苷焦磷酸酶（inosine triphosphate PY-rophosphatase，ITPA）存在个体间的差异，ITPA缺陷的患者在应用嘌呤类药物时会发生一定的不良反应，因此，有必要了解ITPA对嘌呤类药物临床应用的影响，该文综述了ITPA的药理遗传学方面的研究进展。

Purine drugs are for the treatment of autoimmune diseases, organ transplantation, acute lym-phoblastic leukemia. The adverse reaction rate is 15 %-28 %, which impacts on the clinical application in recent years. Studies have shown that inosine triphosphate pyrophosphatase （ITPA） are different between individuals, and there are adverse reactions in patients with defects of ITPA when purine drugs are used. This paper reviewes the ITPA pharrnacogenetic research progresses.